Department of endocrinology, diabetes, and metabolism

UAB startup TIXiMED advances TIX100, a novel oral Type 1 diabetes therapy, into Phase 1b clinical testing. The TXNIP-targeting drug aims to protect insulin-producing beta cells and address disease progression beyond blood sugar management.

Blazer Bridge Fund provides financial support to innovative ideas and inventions by the UAB community, encouraging advanced discovery.